OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Theralase Technologies's OCF Yield % or its related term are showing as below:
TSXV:TLT'
s OCF Yield % Range Over the Past 10 Years
Min: -28 Med: -8.4 Max: -1.6
Current: -4.67
During the past 13 years, the highest OCF Yield % of Theralase Technologies was -1.60%. The lowest was -28.00%. And the median was -8.40%.
TSXV:TLT's OCF Yield % is ranked worse than 70.31% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.76
vs TSXV:TLT: -4.67
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Theralase Technologies OCF Yield % Related Terms
Theralase Technologies OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TSXV:TLT) has a OCF Yield % of -4.67 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Theralase Technologies and its competitors. According to the industry distribution chart, Theralase Technologies ranks #599 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 70.3%.
Is Theralase Technologies' OCF Yield % too high?
Theralase Technologies' current OCF Yield % is -4.67. Based on the distribution chart, Theralase Technologies ranks #599 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 39/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #599 out of 852 companies for OCF Yield %. This places Theralase Technologies in the lower half of its industry. The industry median OCF Yield % is 1.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.76, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current OCF Yield % is -4.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TSXV:TLT) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.18, compared to a current price of C$0.23 — trading 27.8% above its estimated fair value. The current OCF Yield % is -4.67. Theralase Technologies' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Theralase Technologies (TSXV:TLT), the current OCF Yield % is -4.67 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of C$0.23 is trading 27.8% above its estimated GF Value™ of C$0.18.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TSXV:TLT:
OCF Yield %: -4.67
GF Value™: C$0.18 vs. price of C$0.23 (27.8% above fair value)
No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
39GF Score
Get the complete analysis for TSXV:TLT
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:TLT has been successfully added to your 
